Pyridine

Pyridine

SCHEMBL6794846

CCOC(=O)c1cc2c(C)c(OS(=O)(=O)O)ccc2n1C.c1ccncc1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
ELANE P08246 6/20 0.37
KMT2A Q03164 2/20 0.37
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALOX5 P09917 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
F2 P00734 1/20 0.34
PLAU P00749 1/20 0.34
NOD2 Q9HC29 1/20 0.34
NOD1 Q9Y239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246268 0.92 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
Pyridine SCHEMBL6794850 0.90 TSHR (0.39) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL6797552 0.75 KDM4E (0.49) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL6798709 0.72 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
Hydrochloric Acid SCHEMBL13684574 0.70 MAPT (0.52) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL6793054 0.70 MAPT (0.33) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL6793076 0.69 GAA (0.33) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL7882131 0.69 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL7873678 0.68 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2LMNAGAA
SCHEMBL7881078 0.68 KMT2A (0.50) ALDH1A1KDM4ESMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 ALDH1A1 1321/4885KDM4E 1068/4885SMN1; SMN2 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.